A review.We described the availability of medicines and drug susceptibility testing (DST) for the medicines composing the BPaLM regimen for individuals affected by multidrug-resistant or rifampicin-resistant tuberculosis (MDR/RR-TB) in the WHO Europe Region as of Nov. 2023, 1 yr after the WHO recommendation for this 6-mo duration regimen for the treatment of patients affected by MDR/RR-TB (BPaLM) or pre-extensively drug-resistant tuberculosis (pre-XDR-TB; BPaL).The availability of drugs and resistance testing for bedaquiline, pretomanid, linezolid, and moxifloxacin regimen (BPaLM) for rifampicin-resistant tuberculosis, in Europe, is presented.